Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
RZLT
Stock Latest News
Ratings
Rezolute: Positive Risk‑Reward Outlook Despite sunRIZE Miss, Backed by Encouraging Hyperinsulinism Data and Solid Cash Position
11d ago
RZLT
Premium
The Fly
Rezolute reports Q2 EPS (22c), consensus (18c)
12d ago
RZLT
Premium
Pre-Earnings
RZLT Earnings this Week: How Will it Perform?
15d ago
RZLT
Premium
The Fly
Rezolute price target raised to $2 from $1 at Wedbush
2M ago
RZLT
Premium
Ratings
Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
2M ago
RZLT
Premium
Ratings
Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
2M ago
RZLT
Premium
Ratings
Rezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential
2M ago
RZLT
Premium
The Fly
Rezolute shares findings from Expanded Access Program in tumor HI
2M ago
RZLT
Premium
The Fly
Rezolute shares observations from Phase 3 sunRIZE study in congenital HI
2M ago
RZLT
Premium
Company Announcements
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans
2M ago
8K
RZLT
Premium
The Fly
Rezolute price target lowered to $4 from $20 at Maxim
2M ago
RZLT
Premium
The Fly
Rezolute price target lowered to $6 from $15 at Guggenheim
2M ago
RZLT
Premium
The Fly
Rezolute price target lowered to $5 from $14 at H.C. Wainwright
2M ago
RZLT
Premium
The Fly
Rezolute downgraded to Hold from Buy at Craig-Hallum
2M ago
RZLT
Premium
The Fly
Rezolute price target lowered to $5 from $17 at BTIG
2M ago
RZLT
Premium
The Fly
Rezolute downgraded to Market Perform from Outperform at Citizens
2M ago
RZLT
Premium
The Fly
Rezolute downgraded to Neutral from Overweight at Cantor Fitzgerald
2M ago
RZLT
Premium
The Fly
Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss
2M ago
RZLT
Premium
Ratings
Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug
2M ago
RZLT
Premium
The Fly
Rezolute downgraded to Neutral from Outperform at Wedbush
2M ago
RZLT
Premium
The Fly
Xoma price target lowered to $45 from $58 at Leerink
2M ago
RZLT
XOMA
Premium
The Fly
Rezolute Inc trading resumes
2M ago
RZLT
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
